These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years]. Nasu Y; Abe M; Ono N; Araki M; Horimi T; Takahashi I Jpn J Antibiot; 2004 Oct; 57(5):438-48. PubMed ID: 15655905 [TBL] [Abstract][Full Text] [Related]
5. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. Bonfiglio G; Carciotto V; Russo G; Stefani S; Schito GC; Debbia E; Nicoletti G J Antimicrob Chemother; 1998 Feb; 41(2):307-10. PubMed ID: 9533479 [TBL] [Abstract][Full Text] [Related]
6. [Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens]. Sacha PT; Jakoniuk P; Wieczorek P; Zalewska M; Leszczyńska K Med Dosw Mikrobiol; 2004; 56(3):263-73. PubMed ID: 15773503 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa. Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715 [TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States. Sader HS; Huband MD; Castanheira M; Flamm RK Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652 [No Abstract] [Full Text] [Related]
9. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. Oie S; Sawa A; Kamiya A; Mizuno H J Antimicrob Chemother; 1999 Nov; 44(5):689-91. PubMed ID: 10552987 [TBL] [Abstract][Full Text] [Related]
10. [Performance evaluation of VITEK 2 system in meropenem susceptibility testing of clinical Pseudomonas aeruginosa isolates]. Acuner IC; Bayramoğlu G; Birinci A; Cekiç Cihan C; Bek Y; Durupınar B Mikrobiyol Bul; 2011 Jul; 45(3):411-21. PubMed ID: 21935774 [TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Sader HS; Castanheira M; Mendes RE; Flamm RK; Farrell DJ; Jones RN Antimicrob Agents Chemother; 2015; 59(6):3656-9. PubMed ID: 25845861 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Erdem I; Kucukercan M; Ceran N Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429 [TBL] [Abstract][Full Text] [Related]
13. Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units. Vojtová V; Kolár M; Hricová K; Uvízl R; Neiser J; Blahut L; Urbánek K New Microbiol; 2011 Jul; 34(3):291-8. PubMed ID: 21811750 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer. Hachem R; Reitzel R; Rolston K; Chaftari AM; Raad I Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115350 [TBL] [Abstract][Full Text] [Related]
15. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). Nichols WW; de Jonge BL; Kazmierczak KM; Karlowsky JA; Sahm DF Antimicrob Agents Chemother; 2016 Aug; 60(8):4743-9. PubMed ID: 27216074 [TBL] [Abstract][Full Text] [Related]
16. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs]. Watanabe Y; Fujiue Y; Yano S; Shimizu S; Muroki K; Doi M; Kuwabara M Jpn J Antibiot; 2006 Apr; 59(2):65-71. PubMed ID: 16805317 [TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014). Sader HS; Castanheira M; Jones RN; Flamm RK Diagn Microbiol Infect Dis; 2017 Mar; 87(3):261-265. PubMed ID: 28069328 [TBL] [Abstract][Full Text] [Related]
18. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. Shortridge D; Pfaller MA; Castanheira M; Flamm RK Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729 [TBL] [Abstract][Full Text] [Related]
19. Direct antibiotic susceptibility testing of blood cultures of gram-negative bacilli using the Drug Susceptibility Testing Microfluidic (DSTM) device. Mizoguchi M; Matsumoto Y; Saito R; Sato T; Moriya K J Infect Chemother; 2020 Jun; 26(6):554-562. PubMed ID: 32115345 [TBL] [Abstract][Full Text] [Related]
20. Mature Pseudomonas aeruginosa biofilms prevail compared to young biofilms in the presence of ceftazidime. Bowler LL; Zhanel GG; Ball TB; Saward LL Antimicrob Agents Chemother; 2012 Sep; 56(9):4976-9. PubMed ID: 22777043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]